From: CircFBXL5 promotes the 5-FU resistance of breast cancer via modulating miR-216b/HMGA2 axis
Clinicopathologic features | Relative circFBXL5 level | P value | |
---|---|---|---|
High (%) | Low (%) | ||
Age (years) | Â | Â | 0.2493 |
 ≥ 55 | 15 (55.6) | 12 (44.4) |  |
 < 55 | 9 (75.0) | 3 (25.0) |  |
Tumor size (cm) | Â | Â | 0.0181* |
 ≥ 3 | 10 (90.9) | 1 (9.1) |  |
 < 3 | 14 (50.0) | 14 (50.0) |  |
TNM stage | Â | Â | 0.0052* |
 I + II | 12 (46.2) | 14 (53.8) |  |
 III | 12 (92.3) | 1 (7.7) |  |
ER status | 0.8759 | ||
 Negative | 9 (60.0) | 6 (40.0) |  |
 Positive | 15 (62.5) | 9 (37.5) |  |
PR status | 0.6729 | ||
 Negative | 8 (57.1) | 6 (42.9) |  |
 Positive | 16 (64.0) | 9 (36.0) |  |
HER2 status | 0.2677 | ||
 Negative | 17 (680.0) | 8 (32.0) |  |
 Positive | 7 (50.0) | 7 (50.0) |  |